Table 1.
Open in new tab

Ivermectin Trials Providing Results on Loa loa Microfilaremia Included in the Analysis

ReferenceCountrySex, Age Range, yInclusion Criteria for IVM TreatmentBlood Sample/ProcessingIVM Dose, µg/kgNo. of ParticipantsaInitial MFD (WGM) [range], mf/mL
[13]Republic of CongoM+F, NAMFD >0 mf/mL2 × 20 µL/leucoconcentration if no mf in blood smears200285850 [2500–46 000]
[14]CameroonM+F, >5MFD >0 mf/mL30 µL200801914 [33–139 086]
[15]CameroonM+F, 19–60MFD >30 mf/mL30 µL20011215 725 [633–164 550]
[10]GabonM+F, 15–76MFD >0 mf/mL10 µL + 4 mL if no mf in blood smear2007139 [0.25–35 700]
[9]CameroonM+F, ≥15Random sampling in 7 microfilaremia strata50 µL150533503.8 [0–198 660]
[16]CameroonM+F, 18–705 ≤ MFD ≤ 150 mf/mL50 µL15013535 [80–2240]
[17]CameroonM+F, ≥15–70100 ≤ MFD ≤ 15 000 mf/mL50 µL150313261 [420–16 220]
[18]GabonM+F, 7–78Symptoms of loiasis4 mL/leucoconcentration if no mf found in 10-µL aliquot20084129.3 [NA]
[19]Cameroon-GabonM+F, NAMFD >0 mf/mLNA20071222 [300–11 150]
[20]CameroonM+F, 2–81Not documented30 µL2004488813 [67–101 690]
[21]GabonM, 18–70Moderate loiasis3–5 mL/leucoconcentration1505 (group 1)290 [NA]
M, 18–70MFD >0 mf/mL & infected with O. volvulus2005 (group 2)292 [NA]
M+F, 13–7220017 (group 3)222 [NA]
ReferenceCountrySex, Age Range, yInclusion Criteria for IVM TreatmentBlood Sample/ProcessingIVM Dose, µg/kgNo. of ParticipantsaInitial MFD (WGM) [range], mf/mL
[13]Republic of CongoM+F, NAMFD >0 mf/mL2 × 20 µL/leucoconcentration if no mf in blood smears200285850 [2500–46 000]
[14]CameroonM+F, >5MFD >0 mf/mL30 µL200801914 [33–139 086]
[15]CameroonM+F, 19–60MFD >30 mf/mL30 µL20011215 725 [633–164 550]
[10]GabonM+F, 15–76MFD >0 mf/mL10 µL + 4 mL if no mf in blood smear2007139 [0.25–35 700]
[9]CameroonM+F, ≥15Random sampling in 7 microfilaremia strata50 µL150533503.8 [0–198 660]
[16]CameroonM+F, 18–705 ≤ MFD ≤ 150 mf/mL50 µL15013535 [80–2240]
[17]CameroonM+F, ≥15–70100 ≤ MFD ≤ 15 000 mf/mL50 µL150313261 [420–16 220]
[18]GabonM+F, 7–78Symptoms of loiasis4 mL/leucoconcentration if no mf found in 10-µL aliquot20084129.3 [NA]
[19]Cameroon-GabonM+F, NAMFD >0 mf/mLNA20071222 [300–11 150]
[20]CameroonM+F, 2–81Not documented30 µL2004488813 [67–101 690]
[21]GabonM, 18–70Moderate loiasis3–5 mL/leucoconcentration1505 (group 1)290 [NA]
M, 18–70MFD >0 mf/mL & infected with O. volvulus2005 (group 2)292 [NA]
M+F, 13–7220017 (group 3)222 [NA]

Abbreviations: IVM, ivermectin; MFD, microfilarial density; WGM, Williams geometric mean.

aWith at least 1 post-treatment measure.

Table 1.
Open in new tab

Ivermectin Trials Providing Results on Loa loa Microfilaremia Included in the Analysis

ReferenceCountrySex, Age Range, yInclusion Criteria for IVM TreatmentBlood Sample/ProcessingIVM Dose, µg/kgNo. of ParticipantsaInitial MFD (WGM) [range], mf/mL
[13]Republic of CongoM+F, NAMFD >0 mf/mL2 × 20 µL/leucoconcentration if no mf in blood smears200285850 [2500–46 000]
[14]CameroonM+F, >5MFD >0 mf/mL30 µL200801914 [33–139 086]
[15]CameroonM+F, 19–60MFD >30 mf/mL30 µL20011215 725 [633–164 550]
[10]GabonM+F, 15–76MFD >0 mf/mL10 µL + 4 mL if no mf in blood smear2007139 [0.25–35 700]
[9]CameroonM+F, ≥15Random sampling in 7 microfilaremia strata50 µL150533503.8 [0–198 660]
[16]CameroonM+F, 18–705 ≤ MFD ≤ 150 mf/mL50 µL15013535 [80–2240]
[17]CameroonM+F, ≥15–70100 ≤ MFD ≤ 15 000 mf/mL50 µL150313261 [420–16 220]
[18]GabonM+F, 7–78Symptoms of loiasis4 mL/leucoconcentration if no mf found in 10-µL aliquot20084129.3 [NA]
[19]Cameroon-GabonM+F, NAMFD >0 mf/mLNA20071222 [300–11 150]
[20]CameroonM+F, 2–81Not documented30 µL2004488813 [67–101 690]
[21]GabonM, 18–70Moderate loiasis3–5 mL/leucoconcentration1505 (group 1)290 [NA]
M, 18–70MFD >0 mf/mL & infected with O. volvulus2005 (group 2)292 [NA]
M+F, 13–7220017 (group 3)222 [NA]
ReferenceCountrySex, Age Range, yInclusion Criteria for IVM TreatmentBlood Sample/ProcessingIVM Dose, µg/kgNo. of ParticipantsaInitial MFD (WGM) [range], mf/mL
[13]Republic of CongoM+F, NAMFD >0 mf/mL2 × 20 µL/leucoconcentration if no mf in blood smears200285850 [2500–46 000]
[14]CameroonM+F, >5MFD >0 mf/mL30 µL200801914 [33–139 086]
[15]CameroonM+F, 19–60MFD >30 mf/mL30 µL20011215 725 [633–164 550]
[10]GabonM+F, 15–76MFD >0 mf/mL10 µL + 4 mL if no mf in blood smear2007139 [0.25–35 700]
[9]CameroonM+F, ≥15Random sampling in 7 microfilaremia strata50 µL150533503.8 [0–198 660]
[16]CameroonM+F, 18–705 ≤ MFD ≤ 150 mf/mL50 µL15013535 [80–2240]
[17]CameroonM+F, ≥15–70100 ≤ MFD ≤ 15 000 mf/mL50 µL150313261 [420–16 220]
[18]GabonM+F, 7–78Symptoms of loiasis4 mL/leucoconcentration if no mf found in 10-µL aliquot20084129.3 [NA]
[19]Cameroon-GabonM+F, NAMFD >0 mf/mLNA20071222 [300–11 150]
[20]CameroonM+F, 2–81Not documented30 µL2004488813 [67–101 690]
[21]GabonM, 18–70Moderate loiasis3–5 mL/leucoconcentration1505 (group 1)290 [NA]
M, 18–70MFD >0 mf/mL & infected with O. volvulus2005 (group 2)292 [NA]
M+F, 13–7220017 (group 3)222 [NA]

Abbreviations: IVM, ivermectin; MFD, microfilarial density; WGM, Williams geometric mean.

aWith at least 1 post-treatment measure.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close